Promising effects of 3rd line cyclophosphamide, adriamycin and vincristine (CAV) and 4th line ifosfamide and carboplatin chemotherapy in refractory small cell lung cancer
نویسندگان
چکیده
Third and fourth line chemotherapy agents are not helpful in the setting of extensive stage small cell lung cancer (SCLC). We describe the case of a 43-year-old Korean patient with T4N3M1b extensive stage SCLC who responded remarkably well to treatment and experienced a prolonged progression-free survival (PFS) period following treatment with fourth line ifosfamide and carboplatin after experiencing disease progression with three previous regimens. Additionally, third line cyclophosphamide, doxorubicin (Adriamycin), and vincristine demonstrated long-term PFS periods.
منابع مشابه
Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line.
Irinotecan is one of the most active drugs used in the treatment of small cell lung cancer (SCLC). 7-Ethyl-10-hydroxy-camptothecin (SN-38) is an active metabolite of irinotecan. We established an SN-38-resistant subline (SBC-3/SN-38) by continuous exposure of SN-38 to a human SCLC cell line, SBC-3. Using the 3-[4, 5-dimethyl-thiazol-2-yl] 2, 5-diphenyltetrazolium bromide assay, we evaluated the...
متن کاملSmall-cell lung cancer: treatment progress and prospects.
Although small-cell lung cancer (SCLC) represents only 20% of all lung cancer cases in the United States, it is the most lethal subtype. Combination chemotherapy unequivocally offers the best chance for improved survival in SCLC. Either PE (platinum plus etoposide) or CAV (cyclophosphamide, Adriamycin, and vincristine) is a reasonable first-line therapy. Alternating PE with CAV does not appear ...
متن کاملSecond-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience
BACKGROUND Randomized trials established topotecan and the combination of adriamycin, cyclophosphamide and vincristine (ACO) as second-line therapy options for small-cell lung cancer. We retrospectively evaluated the outcome of SCLC patients undergoing second-line chemotherapy. PATIENTS AND METHODS 92 consecutive patients with a diagnosis of SCLC between 2000 and 2010 were analyzed. RESULTS...
متن کاملOutpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma.
Approximately 1.5 million people worldwide are living with various forms of lymphoma, and it is estimated that 300 000 people will die each year. In terms of incidence and mortality, non-Hodgkin’s lymphoma (NHL) is the second fastest growing cancer in the USA and the third fastest growing in the rest of the world. Each year ∼60 000 people in the USA will be diagnosed with NHL. More than half of...
متن کاملPleuropulmonary Blastoma: Report of 2 Cases
Pleuropulmonary blastoma (PPB) is a rare, malignant intrathoracic tumor that occurs mostly in children before 5 years old. It consists about 15% of all primary pediatric pulmonary tumors and shows various mesenchymal components. Its presentations are nonspecific and common symptoms include fever, cough, chest pain, respiratory distress, and pulmonary infection. PPB should be considered in the ...
متن کامل